Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17747027 | 1.00 | KMT2A (0.49) | KMT2ATLR2HDAC1HDAC2BCHE | |
| SCHEMBL29602153 | 0.94 | KMT2A (0.47) | KMT2ATLR2HDAC1HDAC2BCHE | |
| SCHEMBL17751722 | 0.94 | KMT2A (0.47) | KMT2ATLR2HDAC1HDAC2BCHE | |
| SCHEMBL19990738 | 0.94 | KMT2A (0.47) | KMT2ATLR2HDAC1HDAC2BCHE | |
| SCHEMBL17747070 | 0.94 | KMT2A (0.47) | KMT2ATLR2HDAC1HDAC2BCHE | |
| SCHEMBL29602180 | 0.94 | KMT2A (0.47) | KMT2ATLR2HDAC1HDAC2BCHE | |
| SCHEMBL17747073 | 0.94 | KMT2A (0.47) | KMT2ATLR2HDAC1HDAC2BCHE | |
| SCHEMBL20009644 | 0.93 | TLR2 (0.43) | KMT2ATLR2HDAC1HDAC2BCHE | |
| SCHEMBL17747041 | 0.91 | TLR2 (0.53) | KMT2ATLR2TLR1 | |
| SCHEMBL17747042 | 0.91 | TLR2 (0.53) | KMT2ATLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230101323-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-30 | — | — | US | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3778622-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3218392-B1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
| US-10633419-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10633419-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
| US-9856292-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856292-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3218392-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160137696-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-19 | — | — | US | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160137696-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-19 | — | — | US | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885TLR2 91/4885HDAC1 1460/4885 |
| US-20160137696-A1 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885TLR2 91/4885HDAC1 1460/4885 |
| US-20230101323-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885TLR2 91/4885HDAC1 1460/4885 |
| US-10633419-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885TLR2 91/4885HDAC1 1460/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885TLR2 91/4885HDAC1 1460/4885 |
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885TLR2 91/4885HDAC1 1460/4885 |
| US-20200216498-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885TLR2 91/4885HDAC1 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.